Bexotegrast-treated patients demonstrated improvements in forced vital capacity (FVC) and reduced cough severity compared to placebo. Bexotegrast was well tolerated at 160 mg over 12 weeks of ...

SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (PLRX), today announced topline data from a 12-week, randomized, double-blind, placebo-controlled trial of ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Following use of race-neutral lung function equations, African American and Latino pediatric ...

This investigation involved analyses of the potential for pulmonary hypertension (PH) and interstitial lung disease (ILD) to have an impact on patients living with systemic sclerosis. The PH or ILD ...